Reference : Genomic and clinical predictors of lacosamide response in refractory epilepsies
Scientific journals : Article
Human health sciences : Neurology
Systems Biomedicine
http://hdl.handle.net/10993/40509
Genomic and clinical predictors of lacosamide response in refractory epilepsies
English
Heavin, Sinéad B. [> >]
McCormack, Mark [> >]
Wolking, Stefan [> >]
Slattery, Lisa [> >]
Walley, Nicole [> >]
Avbersek, Andreja [> >]
Novy, Jan [> >]
Sinha, Saurabh R. [> >]
Radtke, Rod [> >]
Doherty, Colin [> >]
Auce, Pauls [> >]
Craig, John [> >]
Johnson, Michael R. [> >]
Koeleman, Bobby P. C. [> >]
Krause, Roland mailto [University of Luxembourg > Luxembourg Centre for Systems Biomedicine (LCSB) >]
Kunz, Wolfram S. [> >]
Marson, Anthony G. [> >]
O'Brien, Terence J. [> >]
Sander, Josemir W. [> >]
Sills, Graeme J. [> >]
Stefansson, Hreinn [> >]
Striano, Pasquale [> >]
Zara, Federico [> >]
EPIGEN Consortium [> >]
EpiPGX Consortium [> >]
Depondt, Chantal [> >]
Sisodiya, Sanjay [> >]
Goldstein, David [> >]
Lerche, Holger [> >]
Cavalleri, Gianpiero L. [> >]
Delanty, Norman [> >]
2019
Epilepsia Open
0
0
Yes
International
2470-9239
[en] Abstract Objective Clinical and genetic predictors of response to antiepileptic drugs (AEDs) are largely unknown. We examined predictors of lacosamide response in a real-world clinical setting. Methods We tested the association of clinical predictors with treatment response using regression modeling in a cohort of people with refractory epilepsy. Genetic assessment for lacosamide response was conducted via genome-wide association studies and exome studies, comprising 281 candidate genes. Results Most patients (479/483) were treated with LCM in addition to other AEDs. Our results corroborate previous findings that patients with refractory genetic generalized epilepsy (GGE) may respond to treatment with LCM. No clear clinical predictors were identified. We then compared 73 lacosamide responders, defined as those experiencing greater than 75% seizure reduction or seizure freedom, to 495 nonresponders (<25% seizure reduction). No variants reached the genome-wide significance threshold in our case-control analysis. Significance No genetic predictor of lacosamide response was identified. Patients with refractory GGE might benefit from treatment with lacosamide.
Researchers ; Professionals
http://hdl.handle.net/10993/40509
10.1002/epi4.12360
https://onlinelibrary.wiley.com/doi/abs/10.1002/epi4.12360
FP7 ; 279062 - EPIPGX - Epilepsy Pharmacogenomics: delivering biomarkers for clinical use

File(s) associated to this reference

Fulltext file(s):

FileCommentaryVersionSizeAccess
Open access
16577378.pdfPublisher postprint382.3 kBView/Open

Bookmark and Share SFX Query

All documents in ORBilu are protected by a user license.